Thursday, 15 February 2018 11:37 GMT
img

Precision Optics Corporation, Inc. Announces Operating Results for the Second Quarter and Six Months of Fiscal Year 2018 Other OTC:PEYE

(MENAFN Editorial) GARDNER, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the 'Company') today announced operating results on an unaudited basis for its fiscal year 2018 second quarter and six months ended December 31, 2017.

Financial highlights include:

  • 35% increase in quarterly revenues: $813,000 second quarter fiscal 2018 revenues compared to $602,000 in the second quarter of fiscal 2017;
  • 27% increase in six month revenues: $1,841,000 six month fiscal 2018 revenues compared to six month 2017 revenues of $1,451,000;
  • Increased gross margins in Fiscal 2018: 37% gross margin in fiscal 2018 second quarter and six months, compared to 25% and 22% in fiscal 2017 second quarter and six months, respectively;
  • Reduced net loss in Fiscal 2018: Second quarter and six months fiscal 2018 net loss of $60,000 and $89,000, respectively, compared to $312,000 and $605,000 in fiscal 2017 second quarter and six months, respectively.
  • Commenting on the second quarter results, Joseph Forkey, Company CEO said, 'Continued strength in our financial performance at current sales levels reinforces our confidence that the Company will achieve improved operational results when increasing manufacturing orders raise overall revenue levels. Our focus on controlling costs, optimizing the use of resources and maximizing production yields is reflected in increased revenues and gross margins with simultaneous reductions in operating expenses and net losses in both the quarter and six months ended December 31, 2017.'

    Dr. Forkey continued, 'Our sustained pipeline of engineering design projects calls upon our many unique technical capabilities including Microprecision™ micro-optics, custom design of medical grade cameras and endoscopes, CMOS imaging systems, illumination technologies, and 3D endoscopes. We are pleased to report that a number of engineering projects are transitioning to production, and we have now received production orders from three existing customers totaling over $2.1 Million with deliveries scheduled over the next eighteen months. Each of these three products utilizes our proprietary Microprecision™ technologies, and should significantly contribute to increasing revenues and continuously improving operational results in coming quarters.'

    Quarterly Conference Call Details
    The Company has scheduled a conference call to discuss the fiscal Second quarter 2018 financial results for Wednesday, February 14, 2018 at 5:00 PM Eastern Time. To participate in the conference call, please dial 1-844-826-3042 toll free from the U.S., or 1-412-317-5187 for international callers, and ask to be connected to the Precision Optics, Corp. call.

    An audio replay of the conference call will be available approximately one hour after the conclusion of the call and will be made available until February 28, 2018. The audio replay can be accessed by dialing 1-877-344-7529 toll free from the U.S., or 1-412-317-0088 for international callers, and entering Replay Access Code 10116867.

    About Precision Optics Corporation
    Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, MicroprecisionTM micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for a broad range of customers including some of the largest global medical device companies. The Company's innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures. The Company's website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on .

    About Forward-Looking Statements
    This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

    Company Contact:
    Precision Optics Corporation
    22 East Broadway
    Gardner, Massachusetts, 01440-3338
    Telephone: 978-630-1800

    Investor Contact:
    PCG Advisory Group
    Kirin M. Smith
    Chief Operating Officer
    Telephone: 646-863-6519
    Email:
    Website: www.PCGAdvisory.com

    Following are the Company's consolidated balance sheets as of December 31, 2017 and June 30, 2017, and statements of operations for the three and six months ended December 31, 2017 and 2016 and statements of cash flows for the six months ended December 31, 2017 and 2016 (unaudited):

    PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS
    (UNAUDITED)

    December 31,
    2017 June 30,
    2017 ASSETS CURRENT ASSETS Cash and Cash Equivalents $ 381,752 $ 118,405 Accounts Receivable, net 753,152 468,548 Inventories, net 987,791 1,055,447 Prepaid Expenses 78,432 55,985 Total Current Assets 2,201,127 1,698,385 PROPERTY AND EQUIPMENT Machinery and Equipment 2,507,190 2,507,190 Leasehold Improvements 553,596 553,596 Furniture and Fixtures 148,303 148,303 3,209,089 3,209,089 Less: Accumulated Depreciation and Amortization (3,152,639 ) (3,136,835 ) Net Fixed Assets 56,450 72,254 Patents, net 47,275 30,086 TOTAL ASSETS $ 2,304,852 $ 1,800,725 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Current Portion of Capital Lease Obligation $ 8,672 $ 8,391 Accounts Payable 699,507 694,958 Customer Advances 463,289 180,137 Accrued Employee Compensation 179,601 189,783 Accrued Professional Services 107,500 71,000 Accrued Warranty Expense 25,000 25,000 Other Accrued Liabilities 46,125 49,512 Total Current Liabilities 1,529,694 1,218,781 Capital Lease Obligation, net of current portion 19,156 23,564 STOCKHOLDERS' EQUITY Common Stock, $0.01 par value - Authorized - 50,000,000 shares; Issued
    and Outstanding – 10,095,139 shares at December 31, 2017 and
    8,872,916 shares at June 30, 2017 100,952 88,729 Additional Paid-in Capital 45,414,893 45,140,383 Accumulated Deficit (44,759,843 ) (44,670,732 ) Total Stockholders' Equity 756,002 558,380 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,304,852 $ 1,800,725 PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF OPERATIONS
    FOR THE THREE AND SIX MONTHS ENDED
    DECEMBER 31, 2017 AND 2016
    (UNAUDITED)

    Three Months
    Ended December 31, Six Months
    Ended December 31, 2017 2016 2017 2016 Revenues $ 812,773 $ 601,590 $ 1,841,519 $ 1,451,138 Cost of Goods Sold 512,551 453,183 1,154,555 1,135,680 Gross Profit 300,222 148,407 686,964 315,458 Research and Development Expenses, net 90,031 119,215 208,458 236,207 Selling, General and Administrative Expenses 270,035 342,487 566,619 686,269 Gain on Sale of Assets - (1,200 ) - (1,515 ) Total Operating Expenses 360,066 460,502 775,077 920,961 Operating Loss (59,844 ) (312,095 ) (88,113 ) (605,503 ) Interest Expense (482 ) - (998 ) - Net Loss (60,326 ) (312,095 ) (89,111 ) (605,503 ) Loss Per Share: Basic $ (0.01 ) $ (0.04 ) $ (0.01 ) $ (0.08 ) Diluted $ (0.01 ) $ (0.04 ) $ (0.01 ) $ (0.08 ) Weighted Average Common Shares Outstanding: Basic 9,979,197 8,104,800 9,543,810 7,822,191 Diluted 9,979,197 8,104,800 9,543,810 7,822,191 PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF CASH FLOWS
    FOR THE SIX MONTHS ENDED
    DECEMBER 31, 2017 AND 2016
    (UNAUDITED)

    Six Months
    Ended December 31, 2017 2016 CASH FLOWS FROM OPERATING ACTIVITIES: Net Loss $ (89,111 ) $ (605,503 ) Adjustments to Reconcile Net Loss to Net Cash Provided From (Used In) Operating Activities - Depreciation and Amortization 15,804 16,019 Gain on Sale of Assets – (1,515 ) Stock-based Compensation Expense 33,028 110,433 Non-cash Consulting Expense (3,387 ) 17,400 Changes in Operating Assets and Liabilities - Accounts Receivable, net (284,604 ) 308,293 Inventories, net 67,656 35,560 Prepaid Expenses (22,447 ) (5,915 ) Accounts Payable 41,586 (168,433 ) Customer Advances 283,152 37,100 Accrued Liabilities 26,318 (22,880 ) Net Cash Provided From (Used In) Operating Activities 67,995 (279,441 ) CASH FLOWS FROM INVESTING ACTIVITIES: Additional Patent Costs (17,189 ) (5,848 ) Purchases of Property and Equipment – (25,843 ) Proceeds from Sale of Assets – 1,515 Net Cash Used In Investing Activities (17,189 ) (30,176 ) CASH FLOWS FROM FINANCING ACTIVITIES: Payment of Capital Lease Obligation (4,127 ) (3,864 ) Gross Proceeds from Private Placement of Common Stock 210,001 780,000 Gross Proceeds from Exercise of Stock Purchase Warrants 6,667 - Net Cash Provided From Financing Activities 212,541 776,136 NET INCREASE IN CASH AND CASH EQUIVALENTS 263,347 466,519 CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 118,405 50,059 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 381,752 $ 516,578 SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: Issuance of Common Stock in Settlement of Accounts Payable $ 40,000 $ – Offering Costs Included in Accounts Payable $ 2,963 $ –


    MENAFN1502201800703653ID1096468130


    Precision Optics Corporation, Inc. Announces Operating Results for the Second Quarter and Six Months of Fiscal Year 2018 Other OTC:PEYE

      Most popular stories  

    Day | Week | Month